Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 6/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069075 | 0.86 | TNKS (0.49) | JAK2LRRK2BTKPLK4TNKS | |
| SCHEMBL9005172 | 0.85 | CCNA2 (0.49) | CCNA2CDK2JAK2LRRK2BTK | |
| SCHEMBL9005166 | 0.85 | SYK (0.47) | JAK2LRRK2BTKPLK4TNKS | |
| SCHEMBL9069855 | 0.85 | CCNA2 (0.49) | CCNA2CDK2JAK2LRRK2BTK | |
| SCHEMBL14078044 | 0.83 | SYK (0.55) | BTKSYKJAK3EGFRLCK | |
| SCHEMBL9005121 | 0.81 | CCNA2 (0.46) | CCNA2CDK2JAK2LRRK2BTK | |
| SCHEMBL9004682 | 0.80 | BTK (0.58) | CCNA2CDK2JAK2LRRK2BTK | |
| SCHEMBL16763697 | 0.78 | BTK (0.60) | BTKJAK3EGFRLCK | |
| SCHEMBL9069060 | 0.75 | BTK (0.58) | JAK2LRRK2BTKPLK4TNKS | |
| SCHEMBL9005178 | 0.74 | BTK (0.65) | BTKJAK3EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| WO-2008116064-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | CCNA2 732/4885CDK2 119/4885JAK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.